JUNE 3, 2024 by Case Western Reserve University Credit: Pixabay/CC0 Public DomainA new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence. The team’s findings, recently published in the...
JUNE 3, 2024 by Virginia Commonwealth University DAGLβ regulation of lipid signaling. Credit: Proceedings of the National Academy of Sciences (2023). DOI: 10.1073/pnas.2304900120A team of researchers from Virginia Commonwealth University, the University of Texas at Austin and the University of Virginia have made progress toward developing a drug candidate for treating chronic pain more safely....
NEW ORLEANS — Medications in development would preserve muscle mass and augment fat loss when used in combination with glucagon-like peptide 1 (GLP-1) receptor agonists taken for weight loss. As drugs such as semaglutide (Wegovy) and the dual agonist glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Zepbound) are producing unprecedented degrees of weight loss in increasing numbers...
May 30, 2024 — Roughly 30 million to 40 million people in the United States, and nearly a billion people worldwide, have sleep apnea. Closure of your upper airway is the hallmark of sleep apnea. And a machine that forces air into your body through a hose and a face mask is the most common,...
May 24, 2024 07:15 AM EDTUpdated 08:02 AM R&DPharma AUTHORKatherine LewinNews [email protected] Novo Nordisk’s semaglutide cut the risk of major cardiovascular events and death from multiple causes in a Phase 3 study involving patients with type 2 diabetes and chronic kidney disease, building the company’s case for expanding the drug in a broad range of...
Novo Nordisk is ”very enagaged” in India, the CFO says, but the weight-loss drug will not be launched there until 2025. Photo: Tom Little BY CHRISTIAN BUNDGAARD28 May 2024at 09:50 People with obesity in India will have to wait to get access to Novo Nordisk’s big seller Wegovy, according to the local Indian media Business...
Medscape Medical News > Conference News > DDW 2024 Damian McNamara, MA May 23, 2024 WASHINGTON, DC — In contrast with a previous study that found glucagon-like peptide 1 (GLP-1) receptor agonists associated with an increased risk for acute pancreatitis and bowel obstruction, a new retrospective study found no significant link to these complications. The...
NEWS Dr. Nina Mörsch | 07 May 2024 Penicillin allergies are less prevalent than often presumed. However, misdiagnosed allergies can prove detrimental to patients requiring antibiotic therapy and contribute to antibiotic resistance. Professor Norma Jung from the University Hospital Cologne, Germany, presented a new recommendation at the 130th Congress of the German Society for Internal...
Test of weight-loss candidate in mice shows that there is still room for improvement in a burgeoning field. By Asher Mullard Researchers adapted a peptide similar to the one used in the obesity drug Wegovy to have an even more potent weight-loss response in mice.Credit: Lise Aaserud/NTB/Alamy With obesity drugs now helping people to slim...
MDedge News >Conference News > AAN 2024 Ted Bosworth May 14, 2024 Two Novel Epilepsy Treatments Headed for Pivotal Trials DENVER — Two new drugs are headed toward pivotal trials after making their endpoints in phase 2 treatment-resistant epilepsy studies, while a first-in-humans study of an implantable product suggests a new direction for this disease,...
